volume 277, issue 1-2, P31-37 2004
DOI: 10.1016/j.ijpharm.2003.09.049
View full text
|
|
Share

Abstract: The dry powder inhaler, which has traditionally relied on the patient's inspiratory force to deaggregate and deliver the active agent to the target region of the lung, has been a successful delivery device for the provision of locally active agents for the treatment of conditions such as asthma and chronic obstructive pulmonary disease (COPD). However, such devices can suffer from poor delivery characteristics and/or poor reproducibility. More recently, drugs for systemic delivery and more high value compounds…

expand abstract